<SEC-DOCUMENT>0000882095-23-000011.txt : 20230605
<SEC-HEADER>0000882095-23-000011.hdr.sgml : 20230605
<ACCEPTANCE-DATETIME>20230425125333
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000882095-23-000011
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iee9eccf1119c4cada8b407ae2905edfc_33"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><img alt="gilead-whitexcolorxtn.jpg" src="gilead-whitexcolorxtn.jpg" style="height:134px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 25, 2023</font></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">VIA EDGAR</font></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jenn Do</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daniel Gordon</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Division of Corporation Finance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office of Life Sciences</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 F Street N.E.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K for the Fiscal Year Ended December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed February 22, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No. 0-19731</font></td></tr></table></div><div style="margin-top:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Ms. Do and Mr. Gordon&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This letter responds to the comments of the staff of the Securities and Exchange Commission&#8217;s Division of Corporation Finance (the &#8220;Staff&#8221;) contained in the Staff&#8217;s letter addressed to Andrew Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (the &#8220;Company&#8221;), dated March 29, 2023, regarding the above-referenced filing. For your convenience, we have repeated the Staff&#8217;s comments before the Company&#8217;s responses below.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K for the fiscal year ended December 31, 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management's Discussion and Analysis of Financial Condition and Results of Operations, page 34</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Results of Operations, page 36</font></div><div style="margin-top:9pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.5pt">We note your analysis of research and development expenses on page 38&#58; &#8220;Research and development expenses increased by $376 million in 2022 compared to 2021, primarily due to higher clinical development spend related mostly to Trodelvy and the Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) collaboration, as well as inflationary increases.&#8221; Given the significance of research and development expenses for the periods presented, please revise your future filings to better disclose the drivers of the changes. As part of your response, disclose the costs incurred during each period presented for each of your key research and development projects. If you do not track your research and development costs by project, please disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense). We note, in this regard, the disclosures provided in your Form 10-K for the year ended December 31, 2020.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acknowledge the Staff&#8217;s comment and confirm that, consistent with our past practice, we manage research and development (R&#38;D) expenses on an aggregate basis and not by specific project, product candidate, therapeutic area or development phase. We manage our R&#38;D efforts on a dynamic basis taking into account unmet medical need, scientific data, probability of technical and regulatory success, market potential and other considerations. We regularly review our R&#38;D portfolio against the criteria noted above and reallocate resources as necessary among our internal and external R&#38;D activities that we believe will support the long-term growth of our business. We currently do not track total R&#38;D expenses by R&#38;D project because these costs generally do not provide a direct indication of the future success or failure of the project. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses are comprised of internal and external expenses. Our internal R&#38;D expenses, such as personnel costs, infrastructure and other support costs, are often shared among projects and we do not track such costs by product candidate. While our external R&#38;D expenses incurred by clinical research organizations are tracked by product candidate, those expenses do not necessarily correlate to the overall R&#38;D efforts attributable to a specific product candidate and can vary significantly from period to period. Accordingly, we believe that disclosure of the external R&#38;D spend by product candidate could be misleading to investors given that it represents only a portion of the total spend. We also believe that disclosing the clinical research organization expenses by product candidate could be harmful to our competitive position and therefore, to our stockholders. For example, if we were to provide such disclosure our ability to negotiate competitive terms with potential clinical research organizations could be negatively affected since third party clinical research organizations would be able to deduce the amounts we pay for certain work related to a product candidate.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the Staff&#8217;s comment, in future filings beginning with the quarter ended March 31, 2023, we will enhance our disclosure to include a statement regarding how we manage our R&#38;D expenses and, as applicable, that we do not track our total R&#38;D expenses by project, product candidate, therapeutic area or development phase. In addition to continuing to provide narrative disclosure about the material drivers affecting period-over-period changes in R&#38;D expenses, in future filings we will also expand our disclosures to provide additional tabular information as to relevant categories of R&#38;D expenses incurred.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is an illustrative example of the disclosure enhancements described above, using the relevant disclosure in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (changes that are in response to the Staff&#8217;s comments are marked).</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&#38;D expenses consist primarily of personnel costs including salaries, benefits and stock-based compensation expense, infrastructure, materials and supplies and other support costs, research and clinical studies performed by contract research organizations and our collaboration partners, and other outside services.</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">We manage our R&#38;D expenses by identifying the R&#38;D activities we expect to be performed during a given period and then prioritizing efforts based on scientific data, probability of successful technical development and regulatory approval, market potential, available human and capital resources and other considerations. We regularly review our R&#38;D activities based on unmet medical need and, as necessary, reallocate resources among our internal R&#38;D portfolio and external opportunities that we believe will best support the long-term growth of our business. We do not track total R&#38;D expenses by product candidate, therapeutic area or development phase.</font></div><div style="margin-top:9pt;padding-left:36pt;padding-right:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The following table provides a breakout of our R&#38;D expenses by major cost type&#58;</font></div><div style="margin-bottom:5pt;margin-top:7pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:75.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, infrastructure and other support costs</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,811&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies and other costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,601&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $376 million in 2022 compared to 2021, primarily due to higher </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">clinical development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> spend </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">on clinical studies and outside services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related mostly to Trodelvy and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">development programs in collaboration with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as inflationary increases.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="iee9eccf1119c4cada8b407ae2905edfc_549755813973"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please do not hesitate to call me at (650) 524-0862 if you have any questions or would like any additional information regarding this matter.</font></div><div style="margin-top:13pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-top:4.5pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.836%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer<br>Gilead Sciences, Inc.</font></td></tr></table></div><div style="margin-top:4.5pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:4.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cc&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Patterson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVP - Corporate Controller and Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, Inc.</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ronald O. Mueller, Partner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gibson, Dunn &#38; Crutcher</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron K. Briggs, Partner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gibson, Dunn &#38; Crutcher</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Jackson, Partner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ernst &#38; Young LLP</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gilead-whitexcolorxtn.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 gilead-whitexcolorxtn.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $L 9 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHIOF)_>H =13?,3^]3?M"^E $E%1_:%]*DH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &^8G]ZC>*_/G]MS_@JU^U)\ ?V
MV&_8]_9V_93T_P"(6H-X;MM2LX8]0G6ZDWK*TGRHFW"JE.\+?ML?\%N/%HW6
M/_!*;P[9K_STU3QY#:_^.R2!JY_K5/F:2;MIHF_R/O*?ASQ#++Z.,JSH4H58
M*</:8BC3;A+9\LYQ=GZ'Z">8G]ZC>*^/_#_Q:_X+2:^N=0_8[^#>A[O^@E\2
MKI__ $G@DKM-#O/^"JVH,O\ PD?A[]G^QC_B2SU;7+I__'H(JJG7539/YIK\
MTCR:_#%?#_'BL/\ *O3E_P"DN1]&;U_OTWSX_P#GL*\C\3?'*V_9M^#^H?%7
M]L;XE>$]$M;&3;-?Z>T\4'*Y6*-)'9Y9FS\J(-S8X%?E?^VY_P '%7Q8^(,E
MQX*_8G\/?\(GHL9:.3QEK5JLNIW2_P!ZWMVW16RG_:WO_N55:M3HQUU?9;GJ
M<(^'/%/&N,E2RVDG"+M*JW:E';[36KUVBF_EJ?KE\:OVE/@1^SGX>7Q3\<OB
M[H/A>Q9?DFUB^6)IO^N:9W2?\!4U\+?'K_@Y._9#\!M<:3\!?AUXI^(%U&/W
M=X\/]DV,G_;2X5IO_(-?B]X[^('CCXG>)YO&OQ*\;:MX@UJ\DW7.J:YJ$MU/
M)_VTD;=4WPJ^%GQ%^-?Q T?X4?"7PA=:]KVM77V;2]+T^'<TC_>+-N^58U7Y
MFE;Y%3YW^6N&IBZST6E_FS^F<A^CIPCE&'^LY]B)5N5-R5_94DDKN[34VEOS
M<T=+Z'W-\1/^#B_]O7XD:K'H7P?\$^#_  M]LN$@TV'3])DU;4))7;:L2M,W
MENS-_"L-?3G[*G[&O_!7+]IK3X?B3^W'^V_XZ\!:'?Q^;%X/\'W<&G:M,I^9
M?,:UC1+/_=^=_P"]LKV'_@F'_P $>/AG^PSH5K\1?B/%9^*?BE=VY^V:XL>Z
MUT977YK:Q5_^^6G8;W_V%^2O>?VU_P!IK1OV-_V8?%W[0FO01W#:!IN[3;2:
M7:+N\=O+MX./[TC)GZUI&C)P]IB).RUM?_+<_*.)N-.'?[0CDG F6T8.4U!5
MG2C.I.3E9>S=12<5K92E=O2RCN][X'?LZ?#C]GOP_<Z!\.H]5,E_)YVH:CK7
MB"\U*ZNI57;N>:ZED?\ \>KTBL;PEJ5]JOARPU/4(8UN+FRCEN$C^[N*Y^6M
MFN[X59'X3B:^(Q.)G5KR<IMZR;;;?FV%%%%!B%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?F7XE.?^#F7P\/^J4NB_=^[]CN&K],/*_V:_-+Q'_RLT^'?
M^R5/_P"D-U7Z8UQX3_EY_C?Z'Z-XBQC[/)M/^8&A^<PKP/\ ;H_;C^$'[!OP
M9N/BQ\4+L75U,SV_AWP_:R+]JUBZ^]Y$>?X>F]ONH*]5^)?Q%\&?"3P)J_Q-
M\=ZQ'IVBZ#ITU_JU]-]V*&-=S,:_FP_;W_;5\>?MY?M"ZE\;/%AN(=+\Q[3P
M?H+S?)I.G*W[N+^[YK_>E?\ O_[.RKQ-9TXJ,=W^"[GI^$GAK4\0<ZE+$-QP
ME&SJ26CD]U3B^\NK5^6.KW11_;)_;9^.O[<7Q-F^)/QL\1F:"&5UT/PY:%EL
M=&@;_EG#"WR[O[TK?._\7^QY'_UTHH_Y9^;_  UYFRO_ $S_ $#R_+\#E."I
MX/!TXTZ4%:,8I))?+\6]6]7J7/#?ACQ/XV\1Z;X.\'Z'<:OK&J7D5KI>G6$7
MFRW<[MM555:_H'_X)._\$O?#/[ GPO\ ^$E\;65IJ7Q0\06\?_"2:Q$JNEC%
MU_L^U;^&)#]YO^6K_.>-B)\\?\$ /^";%KX2\)V_[<WQK\.?\3W6+5T^']C>
M1AVL;%_O7Q_Z:3_P?W(O^NG'ZJ5W82C_ ,O)KT_KS/XU\=?%"IG&.GP]E<[8
M>F[59*_[R:>L;_RQ>C2T<EK=)7*_([_@YY_:#GM_#WP^_98TJ^5/MUS-XEUV
M,=?+B_T>U'^ZS/<M_P!LJ_6_S$_O5_.+_P %M/C%)\;O^"CGQ$O;2[\ZQ\,R
MV_AJP_B\M;956;;_ -O#356.DU1Y5U_+J?.?1^R&.<>(5/$5(WCAHRJ?]O74
M8KUO*Z\T?T2>"?\ D3-)_P"P?!_Z+6MBL?P3_P B9I/_ &#X/_1:UL5V'XG5
M_C2]7^;"BBB@@**;YB?WJXWXT?';X/\ [/'@>;XD?&[X@:=X<T:WPK7FIW&S
M>_\ #&B_>DD/9%!;VH [+S$_O4ZOS3^.'_!PGX9L9YM,_9J^ =]JZI\JZUXO
MN_L%O)_M+;IOE_[^;*\)\2_\%U_V]]9O)+G1QX T6&3[L-OX=GN-G_ I+FK]
MG(39^T5-\Q/[U?B_X;_X+M_MYZ/<)+K7_" :Q%']Z&X\.SV_F?\  H[FOH+]
MF;_@O4GQ'\=Z#\,/C/\ LZ7ECJ'B#5K?3;*^\&:C]NB^T3R+'&K03+'+MW-_
M#OI^SD"=S](****S&-\Q/[U'F)_>K\C?B1_P70_;&\&_$OQ/X'TOP'\/9[/1
M?%6IZ;9S7&GWC2F."ZEA7=_I/WMJU^BG["GQO\9_M+?LD^!OCQ\0;/3K?6/$
MVD_:KZVTN-UMXW\QUQ'O9V_A_O54HN.X'L%-\Q/[U.K\]_\ @I7_ ,%4?VC/
MV./VEX?@W\,O!7@_4-+F\)VFI_:=<M;EIQ+++<1M_JYT7;^[_NT1BY; ?H-O
M%.KX\_X)1?M[?&C]NO2_'FH?%GPKX;TIO"^I65O81^'X9UWK/$TC>9YTDG]V
MOL.DU9V ****0#?,3^]3J\Y_:J^)GB7X*?LU>.?B]X2M;*?5O#/A>]U.QAU"
M)F@>6")Y%\P*P;;\O]ZORWM_^"_7[:<L?_)/?AQN_P"P5>?_ "351BY; ?L=
M17XY?\/]OVV/^B>_#C_P57G_ ,DT?\/]OVV/^B>_#C_P57G_ ,DU7LY ?L7Y
MB?WJ=7Y6_LP?\%JOVM_C1^TWX!^"_BSP3X M=)\3^*(=/U*>PT^\6XCB>)V_
M=[KEEW?+_=K]4JF47'< HHHJ0&^8G]ZCS$_O5\E_\%5?^"@/BC]AKX>^%V^&
M.F:+J7BOQ1J[Q6MMKD,CVZ6<*;KB5ECD1OO-"J_-W-?(/PU_X+Y?M*3?$OPW
M:_%GP3X%M?"MSX@M+?Q'/I>GW*W%O9O+Y<DL?F7++\GWJJ,92 _72BH(KN"Z
MC6:WN(V60;D:/YMZU/4@%-WBG5\B_P#!7?\ :W^-O[''P4\*^/?@;J6DV]]J
MOC)-,NY-8T]KI?*:SN)/E7S$^;='0!]=45^)_P#P_&_X*$_]#1X)_P#"3;_X
M_3O^'X7_  4/_P"AA\$_^$FW_P ?K3V<B>8_:ZF^8G]ZOQQ\+_\ !>[]MO0>
M/$?@GX>:]%_TTTJZLV_[ZCG=?_':^@/@7_P<"_!OQ'=PZ-^T7\'-8\'LY17U
MO1YO[4L-S?Q,JHDZ?]^WJ>211^B%%<O\+OBW\,_C/X*L_B'\*_&^FZ_H=^/]
M%U+2[Q9HG]5ROW6'\2GE>]=-YB?WJD#\T/$?_*S3X=_[)4__ *0W5?IC7YG>
M(_\ E9I\._\ 9*G_ /2&ZK],:X\'_P O/\3_ $/TCQ&_AY-_V T/SF?F/_P<
ME_M+:CX#_9T\,_LR^'[PPW'Q U9KK7BHXETVSV-Y3?[\S0_]^J_%<_\ +2OO
MK_@Y$\6W^M?M^:3X=N9)/L^B_#NQ6WA_A#2W-W)(WX_)7P+7)7;E6DV?V1X)
MY/0RGPWP3@ES5DZLGIJY-VO;M%17H@KZ8_X)1_L.S_MT?M7:9X0U^SE_X0OP
MVL>K^-+B/'[RW#_):;O[UQ)^[_W!)7S/)^ZZU_0]_P $;?V+X/V-OV.]'M?$
M&E+#XN\9;-<\6-)]^"9T_<VI_P"N,)"_[_F4Z-/VM;EZ+?\ R^9/C)QQ+@GA
M&<L/*V)KWIT^ZOK.?_;B_P#)G'H?5UAIUKI=C#I^F6L=O;PPJD-O JJB(/NJ
MJ_P_W:U***]8_P \==V<W\0/&^D_#GP'K7Q U^;;I^A:3<7]XW_3.&)I'_\
M0:_E/^('C'4_B#XEUOX@Z]_Q_>(=2N-3O'_Z;W$[S2?^/-7] W_!<_XYP_!#
M_@G)XRM(;H0ZEXR,'AK3<2??%T_[_P#\EEN:_GGO^;-A_=V?]\UY^,FG44>W
MZG]E?1BR.5#)<9FLU_%J1IQ?E3BV[>3E.S\XG]9W@G_D3-)_[!\'_HM:V*Q_
M!/\ R)FD_P#8/@_]%K6Q7H'\<5?XTO5_FPHHHH(/*?VN_P!JCX??L<_ O5?C
M7\0!)<16>V#2]+M?]?J5XYVPVL?^TS?]\U^$O[27[37Q?_:H^)=Q\8OCEXD^
MV7S2/%I.E6\S_8-%B?Y5MK./G[W]_P#USU]0?\%V/V@]0^)?[6EG\#+:[D_L
M3X=Z2CO#_#)JEW%YDDO^]';M"J_]=9*T/^"'7[(.@_&SXN:O^TCX_P!,^V:3
MX!NH;?P_9R?ZJ?5G3S&G9?NOY$+)M_Z:R_\ 3.M(JVI.Y3_9$_X(=_'+XWZ-
M9^/OV@?%,OPWT>YCWV>CQVOGZW)$?NM()/DL]W]QM[U]?>%_^"$/[ ^A6WEZ
MQHWBW7I?XYM4\63IO_X#;^6G_CM?96R6I*GGD'*?&/BC_@A#^P/KMNPTC1_%
MF@R_P3:7XLG;9_P&X\Q/_':XO]G'_@B7)^SA^V%X5^-MG\9X_$WA#P_]JNX=
M)UG25AU!+YHFCMV\R']U(J>8[?=2OT"HHYI!RA13?,3^]3JDH_G!^.G_ "7G
MQ]_V/^N?^E]Q7[8?\$C_ /E'!\)O^Q7_ /:\M?B?\=/^2\^/O^Q_US_TON*_
M;#_@D?\ \HX/A-_V*_\ [7EK:?PDQ/HZOQC_ ."\'_)^EK_V3O3_ /TIO:_9
MROQC_P""\'_)^EK_ -D[T_\ ]*;VII_$$CW+_@W0_P"1;^,'_8<TG_TFEK]*
MJ_-7_@W0_P"1;^,'_8<TG_TFEK]*JF7Q!$****DH\:_X*&?\F,?%S_LGFK?^
MDKU_/_I<?VJ_TVPE_P!5<WUO;O\ [KRHO_LU?T ?\%#/^3&/BY_V3S5O_25Z
M_ +0_P#D+Z/_ -A>Q_\ 1\5;TOA)D?L+_P ."/V&/^@Q\0__  K/_M5'_#@C
M]AC_ *#'Q#_\*S_[57V[167-(.4^/_A-_P $4/V//@M\5_#?QC\&:EXVDU;P
MKJRZEI4=_P"*/-@\]595\Q/+^9?FK[ IOF)_>IU*[904UY%C'-.KRC]M#]H#
M3_V7/V8O&7QNNI(_M.BZ&[:7"?\ EO>/^[MXE_WIF2D!^0?_  5Q_:$C^/O[
M;WB3[#J'F:)X#B_X1K2V_A\V)O,O)/QF9T_[91U\_P#CSX<>+/ =Q9Z/X[T*
M2SEUO0+'6+.&3_EOIU[%NAE_[Y^]6Q^SW\&/$'[2/QX\)?!(SR37GC#Q)#%J
MNH?>_=.SS7D[?]L_.;_?K] _^"^'[-&EZ-X+\ _M%>#=#BMX/#W_ !2NL1V_
MW8[*3YK/_OB2/RO^WFNCLC,^F/\ @DI^T7)^T+^Q3X8O]<U'[1KWA;_BG-??
MY=SW%JJ1QRM_UTA\E_\ MI7U!7X[_P#!![]H3_A6G[3VL? /6;KRM+^(FD_:
M-/CD&W&J6:LWWO\ ;MV=?^V4=?L16$E9V- KS/\ :0_92^!W[6?AK3_"'Q\\
M$_VWINEZDE_8VW]H3V^RX5'3=NAD3^%J],IN]?[]): ?*\G_  1;_P""<LO_
M #0:3_PI]3_^2:9)_P $5?\ @G1*./@9<I_US\6:G_\ )-?5?F)_>IU5S2)Y
M3XE\<?\ !!3]B#Q'!,?",OC+PS=/'^YN-/\ $S7"QM_USNEE6OA_]M7_ ()&
M?M _LDZ->?$;PMJ<7C_P79Q[KR^T_3_*U+38_P#GI<6J[UEC_O21[_\ <K]N
MJK7$ N(FM;J&-H91M?S.CY]J%.2#E/Y]/V-_VS/BQ^Q3\4$^)?PKO)+S1KR1
M/^$G\(R7?^BZ[:_WE_ABN5_Y9W"_\#^3Y*_>+X)_&7P+^T!\*M$^,GPVU?[9
MHGB&R6ZT^:2+:Y5N-KK_  NK?*PK\2_^"GG[,&F_LF?M>ZUX-\(6,=GX;\06
M*Z[X;MH_NVL4SNLULO\ LQ3;]O\ L5];?\&]/QMU&_\ #_Q _9OU.[WP:/=V
MWB#18?\ G@ETSQW"#_9\Z%)/K*]5+57"(GB/_E9I\._]DJ?_ -(;JOTQK\S_
M !,?^.FOPW_V2MO_ $ANJ_3"O/P?_+S_ !/]#]*\1OX>3?\ 8#0_.9^&O_!R
MY\.[GP]^V1X-^)R1O]C\2^ EM&8?=^T6EU+N_P#(=U#7YTU_0W_P66_8<U#]
MM']D>XM? ^BQWGC;P;</K/A2-5^:Z;9MGM/^VL?3_;CCK^>22.2*X>UNH9(9
M4D='ADAVM&R_*RLK?=KEQ$>6NT^O4_K;P'XFPN><!T<(I?O<->G*/6UVX/T<
M=+]XR['T[_P2 _99C_:T_;H\+>&-8TOS_#OA:3_A)/$JR?=>"W96AB;^'][<
M-"O^Y7]'^R6OS7_X-N/V<A\/_P!EG7/VBM8T_;J/Q!UIXM/FDC^;^SK)GAC_
M #F\YJ_2RNS"1Y:7-W_+H?S3X\<42XBX\JX:$KTL*O91[<RUJ/UYO=?E%!4?
MVA?2C[0OI7A'[?7[:G@+]A;]GK5/C1XQDAFOU5K7PSHKS?O-5U!_]5 O^S_$
M_P#<05T2E&$7)]-3\CR_+\9FN.I8/"0<ZE22C&*W;;LE_F]DM7H?EU_P<@?M
M26WQ*_:&\-?LR>&KWS+'P#:&^USRS\O]IW87;&W^U';A#_VV>OS9O_\ CT?Z
M5O?$#QYXK^*GCS6_B?\ $#5_MVO>(-2FO]5O)/\ EO/*S2-_P'_V2L&__P"/
M1_I7CRE*<G)]3_3;@?ANCPCPOA<IIM-THI2:5KS?O3>R>LF_E9=#^L[P3_R)
MFD_]@^#_ -%K6Q6+X(_Y$[2_^P;#_P"BTK:KVC_,&M_&EZO\V%%%%!F?SX?M
MYW=QJG[<_P 8KZZ\SS?^%AWT7[S^[%LCC_\ '5K]./\ @@K9V5M^P6MQ;?ZR
MY\=:Q+=?[PE5?_052OS]_P""M/PLO/A7_P % O'9F@DCM?$\EOX@L9I(_E=;
MB)(Y-O\ VVMWKZE_X-]?V@](BT3QE^RWJ]W%#>PWS>)?#<4GR^?;RJD-TB_[
MDT*,W_76MI?PR8GZ:44WS$_O4ZL2@K\I;O\ X.'_ (N:?<7EK_PREX;_ -#N
M;B)?^*QG_@E9?^?;_9K]6J_F7US_ )"&L?\ 82OO_1\M:4[=29']&?P!^)&H
M?&;X%^#_ (NZEID=C<>)_#=EJDUC;S>8L#7$"2;%8X^[NKM:\K_8;_Y,O^$_
M_9.]&_\ 2.*O5*SZE'\X/QT_Y+SX^_['_7/_ $ON*_;#_@D?_P HX/A-_P!B
MO_[7EK\3_CI_R7GQ]_V/^N?^E]Q7[8?\$C_^4<'PF_[%?_VO+6T_A)B?1U?C
M'_P7@_Y/TM?^R=Z?_P"E-[7[.5^,?_!>#_D_2U_[)WI__I3>U-/X@D>Y?\&Z
M'_(M_&#_ +#FD_\ I-+7Z55^:O\ P;H?\BW\8/\ L.:3_P"DTM?I54R^((A1
M114E'C7_  4,_P"3&/BY_P!D\U;_ -)7K^?RW_X]X8_]SR_]ZOZ _P#@H9_R
M8Q\7/^R>:M_Z2O7X!:'_ ,AW0_\ L+6/_I2E;TOA)D2?9/&?_0.\6?\ ?G4:
M/LGC/_H'>+/^_.HU_2]3<?[%2JGD'*?BW_P0ZM_$L7_!0*S_ +4L_$$=O_P@
MNK?\A"&\6+=OM,?ZSY=U?M-4?E?[-25G)W=R@K\P?^#@W]H-I9?!7[*VAZCN
MWR-XE\21QG_EDF^&TC;_ +:;Y/\ ME7Z;7%U;6=LUS<SI'#&-SO)\JHHK^>?
M]L?X]O\ M*_M/^.?CO)))]BU75WM]$\S^#2[?]S;_P#D./S?^VM."O(3=CZV
M_P"""OP:T._^*_BW]I7QE=V-M%X?TU-"T'[9=*K/<3_O+J5?F_YY[%_[:5^A
M?[6GP^^&_P"T_P#LX>,/@3?^,-)_XJ+19K>SF_M"+_1[H+NMY?O?P3*C5^$W
M_#+'[2&LV\-__P ,Q^/[FWN8TEMIO^$(O&616V,LJ_NMOW5I_P#PR'^T9%^]
M_P"&4?'_ /L?\4'>?_&*T?*Y7N2G8Q/ _CCQ?\%OB)H_Q&T:S\GQ%X,\00WJ
M0Q_-_I5K*GF1+_LOM=:_HL^%?Q#\/?%WX;Z#\4?"-V)M,\0Z3;ZA8R1R;LQ2
MQ"1?_0J_G3\6?#_XB?#35(=!^(W@/6O#=Y-;?:(;/7-)ELY9%W;?-VS*&9=U
M?JM_P0/_ &@E\<_LZ:Q^S[K>H?\ $P^'NK?\2V&0K_R"[O\ >0[?]R3SHJ4U
MI<<3[ZK\_O\ @X3N-0M/V;/ <MAJ5U9M_P +#16>SO)8&V_8;O\ BC85^@-?
MG_\ \'#G_)L_@/\ [*(G_I#=5$?B')V5SX^_X(Q7FLW7_!1;PA%<^(]2FB?P
M_K.^&XU&65?EM?E;;(Q6OW!K\._^"+'_ "D<\'_]B_KG_I-7[B4324M!1"BB
MF^8GE^9GY:DH_)W_ (.'OL'_  OOX7")=UU_PB6I^9C[VW[5;[?_ &>L7_@W
MW\__ (;$\9^5_JO^%9_Z3_O?;K?;_P"SUY;_ ,%;/VBM*_:)_;9UJX\+:M%=
MZ'X,L8?#NFW$<J,D[Q.\EU*K?Q+YS>5N_P"F5?47_!O+\'+JP\/_ !"_:&U'
M3Y(XM5O;?0-'FD_Y:);;I+C;_P!MI-O_ &SK;:F2C/\ VN;U/@3_ ,'!_P #
MOBGJ:A=.\:>#_P"QO.?Y<7#_ &JSQ_WW-:_]_*_3K[0OI7Y]_P#!P-^SAXG^
M(O[+^D?M*?#.&3_A*?@YKJZU!<6\/[V.Q=E\YE_ZY21P3_\ ;*OJ#]B#]JGP
MU^V/^S#X6^/WA>>+S-7L]FL6:'=]AOTPMQ;-_=VR9_X#7G49<F(G3?7WODUK
M^*9^F\50_MC@K*,XI:^QA+"U?[LJ<I3I-_XJ<]/\+/8?(7_GC7Y ?\'"?["'
MP,\#:1IO[6OPQM9=%\:>,/%D6D:EH.GPK]EURZG25OM.S'[J?]W\[+_K?]_Y
MZ_8:OS]_X*E:%%\8_P!O;]D/]GBYM'FT^?QEJ/B358?X6CL([>9=WX+-3QD8
MRP[5M6TEZMV(\*,TQF3\:4<31J.$(PJSJ)/25.G2G4E%]&GR+TW6J1]=?LN_
M!:S_ &=OV=?!?P.TZ",Q^%?#MKI\C1_=DE2-/,D_X%)N:NSO?$WA[2K.2_U+
M7+:V@A_UTUQ,J*GU)K5K^9'_ (*?QR2_\%#_ (T12S?*GCZ^V)YS;8_^ U5:
MM]7BK+3;\#J\.N ZOBEG^)I5L4Z4E%U92Y.=R;FK[RC9WE?=G[4?M>?\%HOV
M(/V5M'FM(/B1;^.O$Z+_ */X9\&W:73;O^FUPNZ&W7UW-N_V:_$7]M']MSXV
M?MU_%Z?XL_&;54CBM]UOX<\-V6[[%H]J?^642M]YFX\R7[[_ .Y\B>/Q_NBG
ME?NU^_\ YVT5Y]:M4K?%]W^9_8G /A)PSP!)XC#WJXAJWM)VNEV@EI&_5ZMK
M2]@K8^'?@B_^)7Q#\-_#K1X9)KKQ!K]CIMLL?WMT\\4:_P#H58]?<'_! K]E
M&Z^//[;EG\6M7TV23P[\+X_[6NIY-VV347^6SC_WE;?/_P!LJGE<FHKJ?9<6
M9]0X9X;Q6:57;V4)-><FK12\W)I(_?:PL8=/LHK"W/[J*,(OX5:HHKVC_+?K
M<**** /B7_@LO^PSKG[4'P@L?BQ\)=#>^\=> XY7MM/M_FEU;3I-C7%JO_34
M;?,C_P!O_?K\B?AI\3/%_P +_'&C_%KX5>*I-'\0:)?)<:;?V_WDE'RM%)&W
MWE;[LD3?P?)7])GE]I:^+?V[_P#@C?\ "S]J;Q!??%GX2:[%X&\<7[-+J<ZV
MIET[69/[]U"K#;+_ --X_G_O*]:0GRZ,F13_ &0_^"V/[.?Q>TFS\-_M&7EM
M\-O%AC6*;^T-PT>];^];W3?+&O\ LS;#7V)X<^)_PT\8VGV_PC\0=%U6'_GM
MINJQ7"_^.,:_#/XP?\$L_P!O3X-Z@UKK7[.NI>(;7S/DU7P7,NI6\G^UY<>)
MU_X%#7BUY\%_B)H,[VM_\#?%MA<?QP_\(;?1?^T!1R1>P<Q_13XO^-?P;^'U
MD^I^//BIX;T:W0;FFU37(+=1_P!_'%?S@ZY+]JO-5EB^=9KZ[>%_^>BM+*R_
M^A5U'A?]E_X\?$&\2+P=^S'XVU6X^_OC\$77[S_@4D7_ +-7O/PI_P"",O[?
MGQ=B4:G\/-)\#V-R'WWWBS5HO-3_ +=;7S'_ .^JJ,5'<3=S]<_V&_\ DR_X
M3_\ 9.]&_P#2.*O5*XK]G[X9W_P=^"'A'X3ZGK$>H7'AGPW8Z9-?6\+1).T$
M"1F0*6/WMOZUVM8]2S^<'XZ?\EY\??\ 8_ZY_P"E]Q7[8?\ !(__ )1P?";_
M +%?_P!KRU^1?QC_ &4/VK]5^-?CC5M*_9=^(EU:W7C;6)K6YM_!UTZ21/?2
MLKJRQ?/\K5^OO_!+7PSXI\#_ /!/[X7^$?&WAJ^T35K#PV$O]+U2S>WGMW\U
MVVM')AE^]6T_A)B?0M?C'_P7>_Y/PMO^R=Z=_P"E5[7[.5^1_P#P6H^ GQ[^
M)G[:UMXG^&?P-\8>)-+C\ V,+ZCH?AZ>ZMQ(L]VQ3S(U*[L-4T_B"1TG_! O
MXL?"SX8>'?BI#\2?B/X?\/R:AKFF-9IKFK06OGJMJ^[R_,8;OO5^AW_#5O[+
MW_1R/@'_ ,+&R_\ CM?@I<?L9_M67^S[3^R+\1'V?<\SP1=?=^[_ ,\JA_X8
ME_:D_P"C./'_ /X0=S_\:JI1C)WN),_?'_AJW]E[_HY'P#_X6-E_\=K<\$_%
M'X:?$R&YN/AS\0-$\01V<OE7DFBZM%=+ Y7.US&S;37\^7_#$O[4G_1G'C__
M ,(.Y_\ C5?I5_P0*^#WQ'^#WPS^)NG_ !'^$NN>%;C4/%MI+:PZYH<MBUU$
MMFB[U\Q1OJ'&RO<I.Y]0?\%#/^3&/BY_V3S5O_25Z_ +0Y(_[4T>7^'^UK%_
M^ K.C?\ LM?T"?MWZ)K_ (G_ &,/BAX<\+Z/<:CJ5]X%U.WL;"SA:66>5H'5
M555^9CFOPTC_ &0_VO-G[W]E'XD?ZO8__%&WG_QJKIOEB*1^^?\ PT9^SY_T
M7CP;_P"%-:__ !RC_AHS]GS_ *+QX-_\*:U_^.5^ ?\ PP_^TQ_T9GXZ_P#"
M"NO_ (U1_P ,/_M,?]&9^.O_  @KK_XU4\D>X<Q^_C?M%?L]AUC_ .%Y^#]S
M?*O_ !4UKW_[:5VU?SH:7^Q'^TS_ &Q82_\ #&?CKY-2M'W_ /"!W7[O;.G_
M $R_NU_1?4RCRC3N?+/_  5Z_:'N/V??V*/$@T'4?)USQ?L\.:*T?^LC>ZW+
M-+_P"%9F_"OR%_8\^ <G[2/[3G@/X#QVG_$OU75D?54C_P"6>FV_[ZX_\AQ^
M57V1_P %NM-_:4_:"_:)T'X;?#3X >.M:\+^!]$:;^T-'\+W4]K/JEW\TC+)
M&O\ RSAC1?\ MK)74?\ !"S]D'XA^ O&_CC]H#XR?#+6O#=_#;1:%X<L_$&E
M26MQL?;-=3JLBAOFVP)_VSJH^[&[%N?I-;V\-M'':VL7EQ)'LCC3Y511QTJU
M11691^?O_!?C]GW_ (3/X#^'_P!I#1=-WZCX"UA;?5'CB7?)I=XR1M\Q_A2;
MR6_[[KX@_P""6'[0?_#.G[;_ (3UC5-3\G2?%TG_  C6O>9M5=MPVZW9O]VX
MV?\ ?VOVV^,WPL\-?&SX3^)/A%XRLXYM+\2:+<Z9?))'N_=RQM'N_#=NK\!]
M;_8D_;+\/7^I>$W_ &:OB'=7.EWTMK_:VG^$[J6*XDAEVK/'(J[?O;&7;6D7
M[MB9']$/F)_>KX!_X.'/^39_ ?\ V41/_2&ZKZN_8\^)GCGXL_LU^#_'GQ0\
M':KX?\2WFB(OB#2=<LY+>XM[R+]W+NCD4-\S*6_&OF?_ (+O?#'XE_%#]G7P
M?I/PN^&^O>)KFS\=)=WMKX?T^6ZE@B^QW"[V6-2V-S"IC\02^$^(_P#@C!<0
M6O\ P47\'S7,L:+_ ,(_K.YY/E^]:U^W7]MZ/Y?F_P!L6^W^]YRU_.)K'P7^
M,FE_Z+KWP-\;6W\?^D>#=1_^,53C^'?Q$E_T2+X9>,7_ .F,?AG46_\ :5:.
M',[B3/Z#?BG^U?\ LS?!+2IM7^*WQW\+Z'%"-[I>:Y%YI^D:MO;_ +YK\Z_V
M]_\ @MI_PL'0;SX.?L7Q:EIME>(\&J?$+4(6M;AX#][^SX6_>+N_Y[R*G^Y_
M'7QG\/\ ]AS]K#QY=I=?#_\ 9%\;7+3?<O)/#+6:?[S27"Q+7U-\ /\ @@G^
MTMX[U"&__:'\8:+X#TGS-\UAH]TNJ:I)C_:V_9HO][]]1&-..H^8^2?V=?V=
M?B/^T_\ %C2_@1\%]-C?5+_8]S?R0[K?2;-6VR7EQ_LI_#_SV^Y7[]?L[? G
MP7^S)\%?#OP,^'EIMTOP[IJ6L$LGWYW^])-)_M/(69O<UB_LP_L@_ O]C_P&
M/ 7P/\%QZ?%-(DNK:I,?-O\ 5IE4+YMQ,WS.W_CB_P (2O5JSE+F>@TK&3K6
M@Z5XDTBY\/Z[I4=U97EN\%S:W"JT<\3KM:-A_=(K\F?A]XA\2_\ !!S]NJ\^
M&/CK[1/^SI\5M2^U:'J\L;R?V//_ 'F_Z:0;A%+_ 'X?+E^_\E?KY7D_[4W[
M+'PI_:^^#&K? _XR^&_MFEZEAX;B%@EQ8W2Y\NZ@D_@D3^'_ +Y;Y2:YJ]%U
M(IPTDG=/]'ZGV?!_$F%R6M6P690=3 XE*%:"W5G[E6'_ $\IOWH]'JGN>C:/
MKNCZ_HUKK6CZE!=6=Y;K/:W%K)YD<T;+E75E^\I'YUY/X_\ V78?&W[8'PY_
M:D35K>%O OA_7-.DL6M_FN#??9_+=6_AV>7-G_KI7YZ_!/\ :/\ VC_^"'_Q
M1M?V6_VTK;4O$OP/U2_9? _Q L;5Y?[-0MN^6,;OD4$^;9_?B^_!O'#_ *I^
M _B)X'^*/@^Q^(7P[\4V.M:'JEK]HTW5-,N%F@NHC_&C+]ZBG4IXB-FK-6NN
MJ>__  Q6?9!FG!F(6)PM55<+7C-4J\5>%2$XN,HN]^6:BVIPE9Q>FJLWT-?S
M*_\ !4#_ )2,?&S_ +*'??\ LM?TS?:%]*_F9_X*@?\ *1CXV?\ 90[[_P!E
MK#&_8]?T9^Q?1C_Y*K&?]>?_ &^)X311_E:V/AY\-_'_ ,6?&6F_#?X9>$+[
M7=<U>Z^SZ7I.GP[I)V_^)7^)ON)7#IU/[.K5J="FZE1J,8IMMM)))7;;>R0?
M#?X=^-_B]XZTCX9?#'PY<:MK^OWB66F:?;_,T\C?^@K_ 'F;Y$K^D#_@G3^P
M_P"&_P!@[]FG2_@_I$UO=:W-(U_XNUJ"'9_:6I2!0[KGD1HH2)/1(QTYKR7_
M ().?\$F/"_["7A#_A9'Q0:PUKXJ:U:[=2U"#YX-'MVY-C:EO_(DO5S_ +-?
M<5>AA:,HOVL]WT[+K]Y_"_C7XJ0XRQ2RG*YMX.E*[EJO:S5[.W\D;M1[MMM?
M"PHHHKL/P,**** "BBB@ J/9^\ZU)10!'LEIVP4ZB@ HHHH CV2T;):DHH *
MC\K_ &:DHH **** "H_*_P!FI** (]DM2444 %%%% !1110!'L?U_P!VCRO]
MFI** "BBB@ J/8/^>/Z5)10!'LEHV-_SSJ2B@!NP4WRO]FI** (_*_V:DHHH
M **** "BBB@#A?C1\$/AA^T)\.=2^%'QC\&6/B'P_J<>VZTZ^AW*2OW75A\T
M<@;YE=?F7VK\V/$/[(G_  4!_P"".WC'4OBI^PGJU]\4O@Y=W;W6N_#/5IGD
MO;!2?F>../[[?W9[=?-Y_>Q2!.?UAJ#[/)_>K*I0A4?-M);-;_\ !/J^&^,,
MRX=ISPO+&OA:O\2A47-3GI:ZZPFEM.+4D[-MV/EG]AG_ (*O_LG?MUV<>C>"
MO%9\/^,?+Q=>"?$4JQWFX?>,.&V7*_\ 7-MW]Y17XA?\%//^4B?QHEQ\K_$2
M^V_^.U^V'[9G_!(#]DG]LJY;QMJ7AN;P?XX$GVB'QOX058+J2<='GC^Y<=OF
M8!_1UKQW]G3_ (-\_A#X<\<WWQ:_;+^+6K?&/Q%>7QN'6_C>VLIV/_+6Y5I)
M);J3_?DV>J-7)4IXJI)0:3MUZ/\ R_$_8_#GC+PUX(QN)SK#U*L/:4^3ZM*/
M/-2NI>Y55H2AHU>;C):-WO<_+?\ 8D_X)Q_M/?MY:_Y/PD\+&S\-I+LU3QIJ
MX>/3K3^\BM_RWD7_ )Y1_P# Z_<C]@7_ ()G_ +_ ()^>#A8?#W3&UCQ1?0*
MNO>-M4C3[9=]_+CV_+! #TBC]MV\_-7T!X;\*:%X.T*U\+^%-%L]-TVP@6*S
ML+&W6&""->BQHF JUN5T4,-&E:4M7_6R/BO$+Q@XBX\YL*OW&$O_  XMMRUN
MG4EHY6>J6D5IIU911170?DP4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
